7 minute Hepatology

Join Prof Ken Liu as we discuss the ins and outs of choosing different systemic therapy of HCC.

Check out EASL Deepdive: https://open.spotify.com/episode/3QlE3JUpMjyGYCifmtHWyp

Article discussed today: Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021; 27(32): 5376-5391 [PMID: 34539139 DOI: 10.3748/wjg.v27.i32.5376]

https://www.wjgnet.com/1007-9327/full/v27/i32/5376.htm

Join Dr Richard Skoien and Dr Alison Kearney as we discuss the Hepatocare model and the importance of appropriate and timely palliative care referral.

Scottish Guidelines:

https://www.palliativecareguidelines.scot.nhs.uk/scottish-palliative-care-guidelines/last-days-of-life-care-around-dying/end-stage-liver-disease/

Hosted by Dr Megan Van Niekerk live at AGW 2026.

Join Prof James O'Beirne and Dr Tim Mitchell as we discuss how to diagnose PFIC and the ins and outs of treating with IBAT inhibitors.

Article 1: Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review

https://link.springer.com/article/10.1186/s13023-025-03599-2

Article 2: Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00093-0/fulltext

Also help support the great work of the liver foundation: https://www.mycause.com.au/page/402888/7-min-hepatology-x-liver-foundation?utm_source=Charity%20-%20Transactional%20Emails&utm_medium=email&utm_campaign=Charity%20-%20Charity%20FRP%20thank%20you%20plus%20receipt%20(272985)&utm_content=VIEW%20FRP

If you are still at AGW, don't forget to donate for your chance to get our plushie.

Join A/Prof Juan Pablo Arab as we discuss using steroids in alcohol associated hepatitis.

Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, Ramírez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, Zhang W, Clark V, Simonetto D, Ahn JC, Buryska S, Mehta TI, Stefanescu H, Horhat A, Bumbu A, Dunn W, Attar B, Agrawal R, Haque ZS, Majeed M, Cabezas J, García-Carrera I, Parker R, Cuyàs B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de la Tijera MF, Kulkarni AV, Rao PN, Guerra Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko KR, Cairo F, de Sousa Coelho M, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Narvaez A, Bessone F, Marcelo JS, Piombino D, Dirchwolf M, Arancibia JP, Altamirano J, Kim W, Araujo RC, Duarte-Rojo A, Vargas V, Rautou PE, Issoufaly T, Zamarripa F, Torre A, Lucey MR, Mathurin P, Louvet A, García-Tsao G, González JA, Verna E, Brown RS, Roblero JP, Abraldes JG, Arrese M, Shah VH, Kamath PS, Singal AK, Bataller R. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021 Nov;75(5):1026-1033. doi: 10.1016/j.jhep.2021.06.019. Epub 2021 Jun 21. PMID: 34166722; PMCID: PMC11090180.

https://pubmed.ncbi.nlm.nih.gov/34166722/

Join A/Prof Juan Pablo Arab as we discuss what is Met-ALD.

Article: https://www.journal-of-hepatology.eu/article/S0168-8278(24)02728-4/pdf

Join Dr Vaitiekunas as he interviews Prof Abraldes answering all the important questions regarding beta blockers in cirrhosis.

Further reading: Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis

https://www.sciencedirect.com/science/article/abs/pii/S0168827825025656

nterested in one of the most unique and trainee focussed hepatology fellowships in Australia?
Watch below ⬇️ ⬇️ ⬇️
Opportunity to tailor your experience in:
1. Dedicated HCC clinic including prescribing immunotherapy with incorporated clinical trials
2. Specialised clinics in PBC and PSC-IBD
3. Options to have specialised clinics in complex portal hypertension/advanced hepatology/MASLD/ARLD
4. Dedicated experience as "consultant on the ward"
5. Portal hypertension endoscopy lists
6. Be part of multiple investigator and the latest phase 3 trials
7. International collaborations
8. Learn from experts in clinical, research and public health
Join us at the Sunshine Coast. What are you waiting for?
To apply: https://lnkd.in/gG9dy_GF
Deadline: 16th June

Join A/Prof Eric Orman as we discuss management of hyponatraemia in cirrhosis?

EASL: https://www.journal-of-hepatology.eu/article/S0168-8278(18)31966-4/fulltext

AASLD: https://journals.lww.com/hep/fulltext/2021/08000/diagnosis,_evaluation,_and_management_of_ascites,.38.aspx

AGA: https://www.gastrojournal.org/article/S0016-5085(25)05959-1/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F

Join Prof Elliot Tapper discussing how to manage falls in cirrhosis.

Article: Falls are an underappreciated driver of morbidity and mortality in cirrhosis

https://journals.lww.com/cld/pages/articleviewer.aspx?year=2022&issue=11000&article=00002&type=Fulltext

Join Prof Elliot Tapper as we discuss how to manage muscle cramps in cirrhosis.

Today's article: Muscle cramps in cirrhosis:

https://journals.lww.com/cld/pages/articleviewer.aspx?year=2024&issue=01010&article=00004&type=Fulltext